Business

LYNKUET® (elinzanetant) Receives Expanded Market Authorization in Canada for Treatment of Moderate to Severe Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy (AET) Related to Breast Cancer

Financial Post · August 17, 2026 at 2:24 p.m.

Expanded authorization introduces a treatment option for women experiencing moderate to severe hot flashes and/or night sweats caused by adjuvant endocrine therapy (AET) related to breast cancer LYNKUET® is the first NK-

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

LYNKUET® (elinzanetant) Receives Expanded Market Authorization in Canada for Treatment of Moderate to Severe Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy (AET) Related to Breast Cancer

More from Financial Post

CUPE, ONA and OPSEU to rally against 101 job cuts at the Queensway-Carleton Hospital in Ottawa, as provincial hospital funding cuts hit patient care

Peripheral Raises $8.7M co-led by Inovia Capital and Deloitte Ventures, to Expand Spatial Intelligence Platform for Live Sports

Copper squeeze builds with spreads surging and price near record

Ideon Technologies Joins Pioneering Global Consortium to Demonstrate High-Resolution Laser-Driven Muon Imaging

More in Business

CUPE, ONA and OPSEU to rally against 101 job cuts at the Queensway-Carleton Hospital in Ottawa, as provincial hospital funding cuts hit patient care

Peripheral Raises $8.7M co-led by Inovia Capital and Deloitte Ventures, to Expand Spatial Intelligence Platform for Live Sports

Copper squeeze builds with spreads surging and price near record

Ideon Technologies Joins Pioneering Global Consortium to Demonstrate High-Resolution Laser-Driven Muon Imaging

Shein is said to target up to US$27 billion valuation in HK IPO

Kaplan Fox & Kilsheimer LLP Alerts HDFC Bank Limited (NYSE: HDB) Investors to a Securities Class Action Deadline on October 13, 2026